Tranexamic Acid for Total Knee Arthroscopy
Blood Loss, Surgical
About this trial
This is an interventional treatment trial for Blood Loss, Surgical
Eligibility Criteria
Inclusion Criteria:
- Adult patients who are scheduled to undergo total knee arthroplasty will be approached to participate.
Exclusion Criteria:
- Known allergy to TXA
- History of venous or arterial thrombosis within 12 months
- History of thromboembolic event within 12 months
- Acute ischemic event (stroke, transient ischemic attack, myocardial infarction, ischemic retinopathy) within 6 months
- Known congenital thrombophilia
Relative Contraindications:
- History of seizures
- Impaired kidney function (Glomerular filtration rate < 30 ml/min)
Sites / Locations
- Miriam Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Tranexamic acid (TXA)
Placebo Normal Saline (NS)
All patients will receive 15 mg/kg Tranexamic acid (TXA) IV prior to skin incision. This arm will receive a second intravenous dose of 15 mg/kg of Tranexamic acid (TXA) before the release of the tourniquet. The medication is delivered from the pharmacy in a masked syringe labeled as "study medication."
All patients will receive 15 mg/kg Tranexamic acid (TXA) IV prior to skin incision. This arm will receive a second intravenous dose of placebo (Normal Saline) in the volume calculated to be equal to the volume of 15 mg/kg of TXA. The medication is delivered from the pharmacy in a masked syringe labeled as "study medication."